AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31113375 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare workers (HCWs)
Number of subjects: 251
Study 31113375 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatients
Number of subjects: 251
Study 31113375 — intervention group
Group type: COMPARATOR
Intervention: Physicians (HCWs)
Number of subjects: 251
Study 31113375 — intervention group
Group type: COMPARATOR
Intervention: Demographic factors in inpatients
Number of subjects: 251
Study 31113456 — intervention group
Group type: EXPERIMENTAL
Intervention: CARDIOROOT vascular graft
Number of subjects: 52
Study 31113467 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum Cyr61 concentration in active RA patients
Number of subjects: 177
Study 31113467 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum Cyr61 concentration in RA patients in remission/low disease activity
Number of subjects: 177
Study 31113467 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum Cyr61 concentration at baseline and 12 weeks after treatment in ACR responders
Number of subjects: 177
Study 31113467 — intervention group
Group type: COMPARATOR
Intervention: Serum Cyr61 concentration at baseline and 12 weeks after treatment in non-responders
Number of subjects: 177
Study 31113766 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 6463
Study 31113766 — intervention group
Group type: COMPARATOR
Intervention: Surgical aortic valve replacement (SAVR)
Number of subjects: 6463
Study 31113766 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR and SAVR (competing risk analysis)
Number of subjects: 6463
Study 31113766 — intervention group
Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 6463
Study 31113766 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep sternal wound infection or vascular access-site infection
Number of subjects: 6463
Study 31113766 — intervention group
Group type: EXPERIMENTAL
Intervention: Type of procedure (TAVR vs SAVR)
Number of subjects: 6463
Study 31113766 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 6463
Study 31113766 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality rate
Number of subjects: 6463
Study 31113777 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab plus carfilzomib and dexamethasone (D-Kd)
Number of subjects: 85
Study 31113837 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous CPX-POM
Number of subjects: 0
Study 31113837 — intervention group
Group type: COMPARATOR
Intervention: Oral CPX-O
Number of subjects: 0
Study 31114182 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 31114211 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction Above Cuff Endotracheal Tube (SACETT)
Number of subjects: 0
Study 31114211 — intervention group
Group type: COMPARATOR
Intervention: Standard Endotracheal Tube (control)
Number of subjects: 0
Study 31114268 — intervention group
Group type: EXPERIMENTAL
Intervention: Grazoprevir/elbasvir in combination with peginterferon alfa plus ribavirin
Number of subjects: 0
Study 31114301 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-shot paravertebral block
Number of subjects: 0
Study 31114301 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 0
Study 31114846 — intervention group
Group type: EXPERIMENTAL
Intervention: Emactuzumab monotherapy
Number of subjects: 0
Study 31114846 — intervention group
Group type: EXPERIMENTAL
Intervention: Emactuzumab in combination with paclitaxel (80 mg/m2 weekly)
Number of subjects: 0
Study 31114846 — intervention group
Group type: EXPERIMENTAL
Intervention: Emactuzumab (1000 mg every 2 weeks)
Number of subjects: 0
Study 31114846 — intervention group
Group type: EXPERIMENTAL
Intervention: Emactuzumab (monotherapy and combination)
Number of subjects: 0
Study 31115158 — intervention group
Group type: EXPERIMENTAL
Intervention: Translated EARP questionnaire (Australian version)
Number of subjects: 250
Study 31115158 — intervention group
Group type: EXPERIMENTAL
Intervention: Translated EARP questionnaire (Korean version)
Number of subjects: 250
Study 31115158 — intervention group
Group type: EXPERIMENTAL
Intervention: Translated EARP questionnaire (Chinese version)
Number of subjects: 250
Study 31115158 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall assessment of patients diagnosed with PsA
Number of subjects: 250
Study 31115278 — intervention group
Group type: COMPARATOR
Intervention: ADHD probands
Number of subjects: 150
Study 31115278 — intervention group
Group type: COMPARATOR
Intervention: Unaffected siblings
Number of subjects: 150
Study 31115343 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention (60-min group-based yoga sessions, 3 times a week for 12 weeks)
Number of subjects: 25
Study 31115343 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention
Number of subjects: 25
Study 31115343 — intervention group
Group type: COMPARATOR
Intervention: Control (maintaining current physical activity levels)
Number of subjects: 25
Study 31115346 — intervention group
Group type: EXPERIMENTAL
Intervention: YMHP intervention (clinic-based delivery)
Number of subjects: 270
Study 31115346 — intervention group
Group type: COMPARATOR
Intervention: YMHP intervention (remote delivery)
Number of subjects: 270
Study 31115904 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 31116012 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP) for obstructive sleep apnea (OSA)
Number of subjects: 129
Study 31116012 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 129
Study 31116012 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated BMI with diabetes diagnosis
Number of subjects: 129
Study 31116012 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoglobin A1c levels
Number of subjects: 129
Study 31116012 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity-associated comorbidities
Number of subjects: 129
Study 31116158 — intervention group
Group type: EXPERIMENTAL
Intervention: SBP at age 40 (mean 128 mmHg, SD 14)
Number of subjects: 2714
Study 31116158 — intervention group
Group type: EXPERIMENTAL
Intervention: DBP at age 40 (mean 78 mmHg, SD 10)
Number of subjects: 2714
Study 31116158 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse pressure at age 40 (mean 50 mmHg, SD 9)
Number of subjects: 2714
Study 31116389 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin, 40 mg per day
Number of subjects: 116
Study 31116389 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time enoxaparin dose adjustment
Number of subjects: 116
Study 31116405 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian tissue transplantation (OTT) after prior chemotherapy exposure
Number of subjects: 31
Study 31116405 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian tissue transplantation (OTT)
Number of subjects: 31
Study 31116676 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulant therapy (initiated in 675 patients, 97%); 600 (89%) treated with low-molecular-weight heparin
Number of subjects: 695
Study 31116676 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulant therapy
Number of subjects: 695
Study 31116676 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsegmental pulmonary embolism
Number of subjects: 695
Study 31116917 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass in adolescents
Number of subjects: 557
Study 31116917 — intervention group
Group type: COMPARATOR
Intervention: Roux-en-Y gastric bypass in adults
Number of subjects: 557
Study 31117854 — intervention group
Group type: EXPERIMENTAL
Intervention: Perinatal risk factors (including fetal distress during labor)
Number of subjects: 174
Study 31117854 — intervention group
Group type: COMPARATOR
Intervention: None of the studied perinatal risk factors
Number of subjects: 174
Study 31118108 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly ONC201 at 625 mg
Number of subjects: 20
Study 31118108 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly ONC201 at 375 mg
Number of subjects: 20
Study 31118108 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly ONC201 (general)
Number of subjects: 20
Study 31118146 — intervention group
Group type: EXPERIMENTAL
Intervention: LAMPOON
Number of subjects: 30
Study 31118244 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with DM1
Number of subjects: 33
Study 31118445 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c <7.0%
Number of subjects: 5770
Study 31118445 — intervention group
Group type: EXPERIMENTAL
Intervention: BP <140/90 mmHg
Number of subjects: 5770
Study 31118445 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL-c <2.6 mmol/L
Number of subjects: 5770
Study 31118445 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined three therapeutic targets
Number of subjects: 5770
Study 31118445 — intervention group
Group type: COMPARATOR
Intervention: Baseline HbA1c ≥7.0%
Number of subjects: 5770
Study 31118445 — intervention group
Group type: COMPARATOR
Intervention: Obese patients
Number of subjects: 5770
Study 31118445 — intervention group
Group type: COMPARATOR
Intervention: Active smokers
Number of subjects: 5770
Study 31118445 — intervention group
Group type: COMPARATOR
Intervention: Patients with physical activities
Number of subjects: 5770
Study 31118571 — intervention group
Group type: EXPERIMENTAL
Intervention: 60-mg dexlansoprazole
Number of subjects: 0
Study 31118571 — intervention group
Group type: EXPERIMENTAL
Intervention: 40-mg esomeprazole
Number of subjects: 0
Study 31118595 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone treatment
Number of subjects: 0
Study 31118595 — intervention group
Group type: COMPARATOR
Intervention: Control group (no testosterone treatment)
Number of subjects: 0
Study 31118759 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin, dosage and duration not specified
Number of subjects: 0
Study 31118779 — intervention group
Group type: EXPERIMENTAL
Intervention: cisplatin, dexamethasone, gemcitabine and pegaspargase (DDGP)
Number of subjects: 0
Study 31118909 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Social Cognition Training (SocialMind)
Number of subjects: 0
Study 31119471 — intervention group
Group type: EXPERIMENTAL
Intervention: cfDNA levels in trauma patients
Number of subjects: 77
Study 31119471 — intervention group
Group type: EXPERIMENTAL
Intervention: MPO and cfDNA correlation in septic patients
Number of subjects: 77
Study 31119471 — intervention group
Group type: EXPERIMENTAL
Intervention: MPO and cfDNA correlation in trauma patients
Number of subjects: 77
Study 31119471 — intervention group
Group type: EXPERIMENTAL
Intervention: H3Cit levels in septic vs trauma patients
Number of subjects: 77
Study 31119471 — intervention group
Group type: EXPERIMENTAL
Intervention: cfDNA prognostic utility in trauma patients
Number of subjects: 77
Study 31119491 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Number of subjects: 42
Study 31119491 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 42
Study 31119693 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg twice daily
Number of subjects: 1041
Study 31119947 — intervention group
Group type: EXPERIMENTAL
Intervention: Catechol
Number of subjects: 0
Study 31119947 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 31120195 — intervention group
Group type: EXPERIMENTAL
Intervention: Doravirine 100 mg coadministered with methadone
Number of subjects: 14
Study 31120195 — intervention group
Group type: COMPARATOR
Intervention: Methadone alone
Number of subjects: 14
Study 31120201 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD
Number of subjects: 472
Study 31120201 — intervention group
Group type: COMPARATOR
Intervention: Comparison youth
Number of subjects: 472
Study 31120355 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib at 75 mg, 100 mg, or 125 mg on days 1-12 of each 21-day cycle plus intravenous bortezomib 1.0 mg/m²
Number of subjects: 0
Study 31120585 — intervention group
Group type: EXPERIMENTAL
Intervention: Auto-titration of EPAP during NIV
Number of subjects: 0
Study 31120585 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 31121167 — intervention group
Group type: EXPERIMENTAL
Intervention: Pi*ZZ carriers
Number of subjects: 554
Study 31121319 — intervention group
Group type: EXPERIMENTAL
Intervention: rs7903146 SNP
Number of subjects: 991
Study 31121319 — intervention group
Group type: EXPERIMENTAL
Intervention: SRH (blood glucose≥11mmol/L in at least two samples during the first 3 days)
Number of subjects: 991
Study 31121428 — intervention group
Group type: EXPERIMENTAL
Intervention: ACLR limb during preparatory and heelstrike phases of gait
Number of subjects: 75
Study 31121428 — intervention group
Group type: EXPERIMENTAL
Intervention: ACLR limb during heelstrike phase
Number of subjects: 75
Study 31121428 — intervention group
Group type: EXPERIMENTAL
Intervention: ACLR limb
Number of subjects: 75
Study 31122047 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual analysis of home sleep examinations
Number of subjects: 0
Study 31122047 — intervention group
Group type: COMPARATOR
Intervention: Automatic analysis of home sleep examinations
Number of subjects: 0
Study 31122213 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating 25-hydroxyvitamin D levels above 50 nmol/L (sufficient)
Number of subjects: 84
Study 31122213 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating 25-hydroxyvitamin D levels below 50 nmol/L (insufficient)
Number of subjects: 84
Study 31122213 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant therapy
Number of subjects: 84
Study 31122221 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with LBP
Number of subjects: 264
Study 31122221 — intervention group
Group type: COMPARATOR
Intervention: Controls without LBP
Number of subjects: 264
Study 31122256 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 424
Study 31122256 — intervention group
Group type: COMPARATOR
Intervention: Non-statin therapy
Number of subjects: 424
Study 31122296 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) at a once-weekly dose of 0.8 mg/kg, up to a maximum dose of 50 mg/week
Number of subjects: 127
Study 31122296 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (ETN)
Number of subjects: 127
Study 31122349 — intervention group
Group type: EXPERIMENTAL
Intervention: CoreValve or Evolut R self-expanding transcatheter aortic valve
Number of subjects: 202
Study 31122966 — intervention group
Group type: EXPERIMENTAL
Intervention: High birth weight (HBW)
Number of subjects: 4981
Study 31122966 — intervention group
Group type: COMPARATOR
Intervention: Normal birth weight (NBW)
Number of subjects: 4981
Study 31122985 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional Picture Set of Self-Injury (EPSI)
Number of subjects: 30
Study 31122985 — intervention group
Group type: COMPARATOR
Intervention: Neutral Picture Set
Number of subjects: 30
Study 31122985 — intervention group
Group type: COMPARATOR
Intervention: Matched Healthy Controls
Number of subjects: 30
Study 31122985 — intervention group
Group type: COMPARATOR
Intervention: Matched Depressive Controls
Number of subjects: 30
Study 31122988 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment for osteonecrosis using MRI scans of the lower limbs and physiotherapy assessment at various time points (within 4 weeks of diagnosis, end of delayed intensification, and 1, 2, and 3 years after the start of maintenance therapy)
Number of subjects: 0
Study 31122988 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical and biochemical data collection at each time point
Number of subjects: 0
Study 31122988 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone mineral density data and vertebral fracture assessment using dual-energy X-ray absorptiometry
Number of subjects: 0
Study 31123002 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive mechanical ventilation (MV)
Number of subjects: 103
Study 31123002 — intervention group
Group type: EXPERIMENTAL
Intervention: Asynchrony index (AI) calculated from ventilator waveforms
Number of subjects: 103
Study 31123002 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival analysis related to AI
Number of subjects: 103
Study 31124321 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 491
Study 31124321 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam Monotherapy
Number of subjects: 491
Study 31124321 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam Polytherapy
Number of subjects: 491
Study 31124321 — intervention group
Group type: COMPARATOR
Intervention: EURAP Registry
Number of subjects: 491
Study 31124321 — intervention group
Group type: COMPARATOR
Intervention: North American AED Pregnancy Registry
Number of subjects: 491
Study 31124335 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib treatment
Number of subjects: 188
Study 31124335 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib treatment in T790M-positive tissue (n=45)
Number of subjects: 188
Study 31124335 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib treatment in T790M-positive plasma (n=54)
Number of subjects: 188
Study 31124335 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebiopsy success rate
Number of subjects: 188
Study 31124471 — intervention group
Group type: EXPERIMENTAL
Intervention: Game play with treatment as usual
Number of subjects: 80
Study 31124471 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 80
Study 31124580 — intervention group
Group type: EXPERIMENTAL
Intervention: Selinexor 60 mg, carfilzomib 20/27 mg/m², dexamethasone (SKd)
Number of subjects: 21
Study 31124989 — intervention group
Group type: EXPERIMENTAL
Intervention: Antireflux surgery
Number of subjects: 62
Study 31124989 — intervention group
Group type: COMPARATOR
Intervention: Preoperative state
Number of subjects: 62
Study 31125298 — intervention group
Group type: EXPERIMENTAL
Intervention: Wingspan Stent system
Number of subjects: 152
Study 31125423 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 600 mg with food
Number of subjects: 60
Study 31125423 — intervention group
Group type: COMPARATOR
Intervention: Pazopanib 800 mg fasted
Number of subjects: 60
Study 31126235 — intervention group
Group type: EXPERIMENTAL
Intervention: Sputum specimens
Number of subjects: 347
Study 31126235 — intervention group
Group type: COMPARATOR
Intervention: Bronchoscopic specimens
Number of subjects: 347
Study 31126235 — intervention group
Group type: EXPERIMENTAL
Intervention: Scanty sputum/bronchoscopy group
Number of subjects: 347
Study 31126243 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher self-reported self-determination
Number of subjects: 134
Study 31126243 — intervention group
Group type: COMPARATOR
Intervention: Lower self-reported self-determination
Number of subjects: 134
Study 31126257 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast cancer cases (surgically intervened)
Number of subjects: 0
Study 31126257 — intervention group
Group type: COMPARATOR
Intervention: Controls (women surgically intervened for breast augmentation or reduction)
Number of subjects: 0
Study 31126280 — intervention group
Group type: EXPERIMENTAL
Intervention: Pars plana vitrectomy (PPV) with sulfur hexafluoride (SF6) gas tamponade
Number of subjects: 62
Study 31126287 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-related delay
Number of subjects: 204
Study 31126287 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare-related delay
Number of subjects: 204
Study 31126287 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous users of inhalation therapy
Number of subjects: 204
Study 31126287 — intervention group
Group type: EXPERIMENTAL
Intervention: Misdiagnosis of respiratory symptoms
Number of subjects: 204
Study 31126291 — intervention group
Group type: EXPERIMENTAL
Intervention: BPD group (26 individuals)
Number of subjects: 96
Study 31126291 — intervention group
Group type: COMPARATOR
Intervention: Preterm group (23 individuals)
Number of subjects: 96
Study 31126291 — intervention group
Group type: COMPARATOR
Intervention: Asthmatics (23 individuals)
Number of subjects: 96
Study 31126291 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (24 individuals)
Number of subjects: 96
Study 31126332 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib (200 mg/bid) plus letrozole (2.5 mg/day)
Number of subjects: 19
Study 31126332 — intervention group
Group type: COMPARATOR
Intervention: Letrozole alone
Number of subjects: 19
Study 31126332 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib and letrozole
Number of subjects: 19
Study 31126336 — intervention group
Group type: EXPERIMENTAL
Intervention: High perceived social support (highest quartile of MSPSS)
Number of subjects: 674
Study 31126336 — intervention group
Group type: COMPARATOR
Intervention: Low perceived social support (below highest quartile of MSPSS)
Number of subjects: 674
Study 31126336 — intervention group
Group type: EXPERIMENTAL
Intervention: High perceived social support among minorities
Number of subjects: 674
Study 31126336 — intervention group
Group type: EXPERIMENTAL
Intervention: High perceived social support among Whites
Number of subjects: 674
Study 31126575 — intervention group
Group type: EXPERIMENTAL
Intervention: CAM treatments (Acupuncture, Reflexology, Guided Imagery)
Number of subjects: 1127
Study 31126575 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 1127
Study 31126763 — intervention group
Group type: EXPERIMENTAL
Intervention: TEVAR for ascending aortic disease
Number of subjects: 6
Study 31126765 — intervention group
Group type: EXPERIMENTAL
Intervention: Valiant Navion stent graft system
Number of subjects: 87
Study 31126836 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency Venous Ablation
Number of subjects: 0
Study 31127422 — intervention group
Group type: EXPERIMENTAL
Intervention: Child self-report version of the State-Trait Anxiety Inventory (STAI)
Number of subjects: 201
Study 31127422 — intervention group
Group type: COMPARATOR
Intervention: Caregiver proxy version (STAI-P)
Number of subjects: 201
Study 31127467 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors (AI)
Number of subjects: 910
Study 31127481 — intervention group
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Number of subjects: 0
Study 31127700 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropathic pain patients
Number of subjects: 60
Study 31127700 — intervention group
Group type: COMPARATOR
Intervention: Antidepressants and antiepileptics
Number of subjects: 60
Study 31127700 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone
Number of subjects: 60